10 December 2024NewsAmericasMuireann Bolger

‘AI curious’ counsel at AZ, Novartis weigh risks and benefits

Corporate legal teams can embrace the AI revolution by encouraging experimentation and managing risks proactively, according to a recent panel featuring leading pharma counsel.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

MSN scores win in battle with Novartis over heart drug generic

22 October 2024 Columbia court backs FDA approval of Entresto generic I Novartis appealing August ruling in Delaware that denied injunction.

Americas

AstraZeneca unit draws line under Samsung dispute

5 September 2024 AstraZeneca unit and Samsung Bioepis resolve their patent dispute over a biosimilar | Settlement follows FDA approval for the generic drug in July 2024 | Agreement dismisses ongoing litigation and appeals, including a federal lawsuit and related patent reviews.

Big Pharma

Novartis fails to block first heart-failure generic by Indian rival

13 August 2024 Delaware judge denies pharma giant’s request for injunction on rivals’ generic of Entresto | Novartis ‘unlikely to succeed’ in proving infringement | Lawsuit is one of several attempts to preserve exclusivity of the drug ahead of patent expiry and US price caps.